Alec  Machiels net worth and biography

Alec Machiels Biography and Net Worth

Alec Machiels is the Founder and Managing Partner of CoLift, a new private equity platform bringing together a global network of leaders with bespoke investment opportunities. He was a Partner at Pegasus Capital Advisors, L.P., a private equity fund manager with approximately $2bn in assets under management. Mr. Machiels was a member of the firm’s executive and investment committees. He has over 20 years of private equity investing and investment banking experience. Previously, Mr. Machiels was a financial analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman Sachs & Co. in New York. Investments in which he has been highly involved include Pure Biofuel, Molycorp Minerals, Traxys, Slipstream Communications, Coffeyville Resources, and Merisant Company. He also co-founded and serves as a board member of Potentia Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. which respectively have drugs in Phase III development to treat macular degeneration and rare diseases. He also served as a member of the board of trustees of the American Federation of Arts, where he chaired the endowment committee. Mr. Machiels is a graduate of Harvard Business School, KU Leuven Law School in Belgium, and Konstanz University in Germany.

What is Alec Machiels' net worth?

The estimated net worth of Alec Machiels is at least $13.95 million as of November 17th, 2023. Mr. Machiels owns 367,420 shares of Apellis Pharmaceuticals stock worth more than $13,954,612 as of July 21st. This net worth evaluation does not reflect any other investments that Mr. Machiels may own. Learn More about Alec Machiels' net worth.

How do I contact Alec Machiels?

The corporate mailing address for Mr. Machiels and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Alec Machiels' contact information.

Has Alec Machiels been buying or selling shares of Apellis Pharmaceuticals?

Alec Machiels has not been actively trading shares of Apellis Pharmaceuticals during the last quarter. Most recently, Alec Machiels sold 1,250 shares of the business's stock in a transaction on Friday, November 17th. The shares were sold at an average price of $47.74, for a transaction totalling $59,675.00. Following the completion of the sale, the director now directly owns 367,420 shares of the company's stock, valued at $17,540,630.80. Learn More on Alec Machiels' trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 45 times. They sold a total of 784,074 shares worth more than $41,486,176.07. The most recent insider tranaction occured on June, 21st when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,451,880.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 6/21/2024.

Alec Machiels Insider Trading History at Apellis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2023Sell1,250$47.74$59,675.00367,420View SEC Filing Icon  
10/17/2023Sell1,250$48.50$60,625.00367,420View SEC Filing Icon  
9/18/2023Sell1,250$45.00$56,250.00367,420View SEC Filing Icon  
9/15/2023Sell1,250$45.34$56,675.00367,420View SEC Filing Icon  
7/17/2023Sell1,250$64.79$80,987.50267,641View SEC Filing Icon  
6/20/2023Sell1,250$88.41$110,512.50267,641View SEC Filing Icon  
5/17/2023Sell1,250$88.66$110,825.00267,641View SEC Filing Icon  
4/17/2023Sell1,250$81.05$101,312.50267,641View SEC Filing Icon  
3/17/2023Sell1,250$64.03$80,037.50267,641View SEC Filing Icon  
1/17/2023Sell1,250$52.42$65,525.00267,641View SEC Filing Icon  
12/15/2022Sell1,250$52.35$65,437.50263,774View SEC Filing Icon  
10/14/2022Sell1,250$59.31$74,137.50263,774View SEC Filing Icon  
9/15/2022Sell1,250$66.00$82,500.00263,774View SEC Filing Icon  
8/15/2022Sell1,250$67.21$84,012.50263,774View SEC Filing Icon  
7/15/2022Sell1,250$46.33$57,912.50263,774View SEC Filing Icon  
6/15/2022Sell1,250$39.29$49,112.50263,774View SEC Filing Icon  
5/16/2022Sell1,250$39.18$48,975.00263,774View SEC Filing Icon  
4/14/2022Sell1,250$50.90$63,625.00263,774View SEC Filing Icon  
3/15/2022Sell1,250$39.57$49,462.50View SEC Filing Icon  
2/15/2022Sell1,250$45.43$56,787.50View SEC Filing Icon  
1/14/2022Sell1,250$40.56$50,700.00View SEC Filing Icon  
7/15/2021Sell2,500$62.30$155,750.00672,044View SEC Filing Icon  
6/15/2021Sell2,500$64.83$162,075.00672,044View SEC Filing Icon  
4/21/2021Sell2,500$45.76$114,400.00672,044View SEC Filing Icon  
3/15/2021Sell2,500$46.77$116,925.00672,044View SEC Filing Icon  
1/15/2021Sell2,500$53.15$132,875.00672,044View SEC Filing Icon  
11/16/2020Sell2,500$39.38$98,450.00672,044View SEC Filing Icon  
10/15/2020Sell2,500$35.00$87,500.00672,044View SEC Filing Icon  
10/7/2020Sell7,500$35.00$262,500.00677,044View SEC Filing Icon  
See Full Table

Alec Machiels Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows Alec Machiels's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $37.98
Low: $37.32
High: $38.59

50 Day Range

MA: $39.97
Low: $34.98
High: $43.60

2 Week Range

Now: $37.98
Low: $19.83
High: $73.80


1,000,244 shs

Average Volume

1,542,776 shs

Market Capitalization

$4.61 billion

P/E Ratio


Dividend Yield